Smith and Williams' Introduction to the Principles of Drug Design and Action

Höfundar: H. John Smith; Hywel Williams (Útgáfa: 4)
Smith and Williams' Introduction to the Principles of Drug Design and Action

Kaup valmöguleikar

Advances in knowledge and technology have revolutionized the process of drug development, making it possible to design drugs for a given target or disease. Building on the foundation laid by the previous three editions, Smith and Williams Introduction to the Principles of Drug Design and Action, Fourth Edition includes the latest informatio

Nánar um bókina

Útgefandi
Taylor & Francis
ISBN
9781135299750
Print ISBN
9781032306612
Format
ePub
Útgáfa
4
Höfundar
H. John Smith; Hywel Williams
Tungumál
English
Útgefið
2005-10-10
Prent takmörkun á líftíma
100
Prent takmörkun
2
Afritunar takmörkun
2

Kaflar

  • Cover Page
  • Title Page
  • Copyright Page
  • Preface
  • List of Contributors
  • Abbreviations
  • 1. Processes of Drug Handling by the Body
  • 1.1 Introduction
  • 1.2 Absorption
  • 1.3 Distribution
  • 1.4 Metabolism
  • 1.5 Removal of Drugs from the Body
  • 1.6 Summary
  • Further Reading
  • 2. The Design of Drug Delivery Systems
  • 2.1 Introduction
  • 2.2 Formulation Aims
  • 2.3 Physico-Chemical Factors Influencing Drug Bioavailability
  • 2.4 Influence of Route of Administration and Type of Dosage Form
  • 2.5 Formulation Factors
  • 2.6 Drug Delivery to the Lung
  • 2.7 Sustained and Controlled Release Dosage Forms
  • 2.8 Site-Specific Drug Delivery
  • 2.9 Bioequivalence
  • Further Reading
  • 3. Intermolecular Forces and Molecular Modelling
  • 3.1 Introduction
  • 3.2 Molecular Interactions
  • 3.3 Free Energies of Interaction—Gas phase and Solution
  • 3.4 Intramolecular Forces and Conformation
  • 3.5 Molecular Modelling
  • 3.6 Proteins
  • 3.7 Accurate Calculation of Intermolecular Interactions
  • References
  • 4. Drug Chirality and Its Pharmacological Consequences
  • 4.1 Introduction
  • 4.2 Definitions and Nomenclature
  • 4.3 Biological Activity
  • 4.4 Pharmacokinetic Considerations
  • 4.5 Pharmacodynamic Considerations
  • 4.6 Selected Therapeutic Groups
  • 4.7 Toxicology
  • 4.8 Racemates Versus Enantiomers: The Future
  • 4.9 Concluding Comment
  • Further Reading
  • 5. Quantitative Structure-Activity Relationships and Drug Design
  • 5.1 Introduction
  • 5.2 Hydrophobicity Parameters
  • 5.3 Electronic Parameters
  • 5.4 Steric Parameters
  • 5.5 Topological Parameters
  • 5.6 Biological Relationships
  • 5.7 Some Limitations and Pitfalls of QSAR
  • 5.8 Multivariate Analysis
  • 5.9 Neural Networks
  • 5.10 Summary
  • Further Reading
  • 6. From Programme Sanction to Clinical Trials: A Partial View of the Quest for Arimidex™, A Potent, Selective Inhibitor of Aromatase
  • 6.1 Introduction
  • 6.2 Background
  • 6.3 ICI Start on Aromatase Inhibition
  • 6.4 Aromatase Resumed
  • 6.5 Bis-Triazole (6.17)—A Timely Aromatase Compound in Development
  • 6.6 The Search for the Ideal Back-Up Candidate
  • 6.7 Into the Clinic
  • Further Reading
  • 7. Pro-Drugs
  • 7.1 Introduction
  • 7.2 Pro-Drug Design
  • 7.3 Application to Pharmaceutical Problems
  • 7.4 Pharmacological Problems
  • 7.5 Summary
  • Further Reading
  • 8. Design of Enzyme Inhibitors as Drugs
  • 8.1 Introduction
  • 8.2 General Aspects of Inhibitor Design
  • 8.3 Rational Approach to the Design of Enzyme Inhibitors
  • 8.4 Development of a Successful Drug for the Clinic
  • 8.5 Stereoselectivity
  • 8.6 Examples of Enzyme Inhibitors as Drugs
  • Further Reading
  • 9. The Chemotherapy of Cancer
  • 9.1 Introduction
  • 9.2 Terminology
  • 9.3 Metastases
  • 9.4 Cell Growth Cycle
  • 9.5 Mechanisms of Tumour Formation
  • 9.6 Treatment
  • 9.7 Antimetabolites
  • 9.8 DNA Interactive Compounds
  • 9.9 Antitubulin Agents
  • 9.10 Miscellaneous Agents
  • 9.11 Immunosuppressive Agents
  • 9.12 Anti-Hormonal Agents
  • 9.13 Enzymes
  • 9.14 Biologicals
  • 9.15 Prodrugs and Drug Targeting Approaches
  • 9.16 New Research Tools
  • 9.17 Future Possibilities
  • 9.18 Anti-Emetics
  • Further Reading
  • 10. Neurotransmitters, Agonists and Antagonists
  • 10.1 Overview
  • Further Reading
  • 10.2 Serotonin Receptors and Ligands
  • Further Reading
  • 10.3 Histamine Receptors
  • Further Reading
  • 10.4 Dopamine Receptors
  • Further Reading
  • 11. Design of Antimicrobial Chemotherapeutic Agents
  • 11.1 Introduction
  • 11.2 Production of Chemotherapeutic Agents
  • 11.3 Mechanism of Action of Chemotherapeutic Agents
  • 11.4 Bacterial Resistance to Chemotherapeutic Agents
  • 11.5 Design of β-Lactam Antibiotics
  • 11.6 Design of Other Antibacterial Agents
  • 11.7 Design of Antifungal Agents
  • 11.8 Design of Antiviral Agents
  • 11.9 Overall Conclusions and Comments
  • Further Reading
  • 12. Recombinant DNA Technology: Monoclonal Antibodies
  • 12.1 Recombinant DNA Technology
  • 12.2 Monoclonal Antibodies
  • Further Reading
  • 13. Bio-Inorganic Chemistry and Its PharmaceuticaL Applications
  • 13.1 Introduction
  • 13.2 The Importance of Trace Elements in Humans
  • 13.3 Metal Coordination Chemistry
  • 13.4 PHarmacological and Pharmaceutical Considerations
  • 13.5 Metals as the Modus Operandi of Drugs
  • 13.6 Drugs which Exert Their Effects Via Metal Complexation or Chelation
  • 13.7 Metal-Dependent Side Effects of Drugs
  • 13.8 Trace Element Supplementation
  • 13.9 Concluding Remarks
  • Further Reading